The siRNA and EGFR short peptide vaccine had a high biocompatibility, showed effective tumor immunotherapy, and had an effective role in the downregulation of the expression of PD-L1 in cells compared to the blank group and the PD-L1-siRNA group [151]. Here, EGFR is linked to neoplasm.